Sham surgery controls in Parkinson's disease clinical trials: Views of participants
dc.contributor.author | Kim, Scott Y.H. | en_US |
dc.contributor.author | De Vries, Raymond | en_US |
dc.contributor.author | Holloway, Robert G. | en_US |
dc.contributor.author | Wilson, Renee | en_US |
dc.contributor.author | Parnami, Sonali | en_US |
dc.contributor.author | Kim, H. Myra | en_US |
dc.contributor.author | Frank, Samuel | en_US |
dc.contributor.author | Kieburtz, Karl | en_US |
dc.date.accessioned | 2012-10-02T17:20:30Z | |
dc.date.available | 2013-10-18T17:47:29Z | en_US |
dc.date.issued | 2012-09-15 | en_US |
dc.identifier.citation | Kim, Scott Y.H.; De Vries, Raymond; Holloway, Robert G.; Wilson, Renee; Parnami, Sonali; Kim, H. Myra; Frank, Samuel; Kieburtz, Karl (2012). "Sham surgery controls in Parkinson's disease clinical trials: Views of participants ." Movement Disorders 27(11): 1461-1465. <http://hdl.handle.net/2027.42/93771> | en_US |
dc.identifier.issn | 0885-3185 | en_US |
dc.identifier.issn | 1531-8257 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/93771 | |
dc.description.abstract | Background: Sham surgery controls are increasingly used in neurosurgical clinical trials in Parkinson's disease (PD) but remain controversial. We interviewed participants of such trials, specifically examining their understanding and attitudes regarding sham surgery. Methods: We conducted semistructured qualitative interviews with participants of 3 sham surgery–controlled trials for PD, focusing on their understanding of sham design, their reactions to it, its impact on decision making, and their understanding of posttrial availability of the experimental intervention and its impact on decisions to participate. Results: All subjects (n = 90) understood the 2‐arm design; most (86%) described the procedural differences between the arms accurately. Ninety‐two percent referred to scientific or regulatory reasons as rationales for the sham control, with 62% specifically referring to the placebo effect. Ninety‐one percent said posttrial availability of the experimental intervention had a strong (48%) or some (43%) influence on their decision to participate, but only 68% understood the conditions for posttrial availability. Conclusions: Most subjects in sham surgery–controlled PD trials comprehend the sham surgery design and its rationale. Although there is room for improvement, most subjects of sham surgery trials appear to be adequately informed. © 2012 Movement Disorder Society | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Sham Surgery | en_US |
dc.subject.other | Bioethics | en_US |
dc.subject.other | Parkinson's Disease | en_US |
dc.subject.other | Gene Therapy | en_US |
dc.title | Sham surgery controls in Parkinson's disease clinical trials: Views of participants | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Medical Education, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Center for Bioethics and Social Sciences in Medicine, University of Michigan, 300 North Ingalls Street, 7C27, Ann Arbor, MI 48109, USA | en_US |
dc.contributor.affiliationother | Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York, USA | en_US |
dc.contributor.affiliationother | Department of Neurology, University of Rochester, Rochester, New York, USA | en_US |
dc.contributor.affiliationother | Department of Community and Preventive Medicine, University of Rochester, Rochester, New York, USA | en_US |
dc.contributor.affiliationother | Department of Neurology, Boston University, Boston, Massachusetts, USA | en_US |
dc.contributor.affiliationother | Department of Environmental Medicine, University of Rochester, Rochester, New York, USA | en_US |
dc.identifier.pmid | 22927064 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/93771/1/25155_ftp.pdf | |
dc.identifier.doi | 10.1002/mds.25155 | en_US |
dc.identifier.source | Movement Disorders | en_US |
dc.identifier.citedreference | Gross RE, Watts RL, Hauser RA, et al. Intrastriatal transplantation of microcarrier‐bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double‐blind, randomised, controlled trial. Lancet Neurol 2011; 10: 509 – 519. | en_US |
dc.identifier.citedreference | Macklin R. The ethical problems with sham surgery in clincial research. N Engl J Med 1999; 341: 992 – 996. | en_US |
dc.identifier.citedreference | Pollack A. Parkinson's patients suing Amgen over drug. New York Times April 27, 2005. | en_US |
dc.identifier.citedreference | Agrawal M, Emanuel EJ. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA 2003; 290: 1075 – 1082. | en_US |
dc.identifier.citedreference | Frank S, Kieburtz K, Holloway R, Kim SYH. What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology 2005; 65: 1101 – 1103. | en_US |
dc.identifier.citedreference | Kim SYH, Schrock L, Wilson RM, et al. An approach to evaluating the therapeutic misconception. IRB 2009; 31: 7 – 14. | en_US |
dc.identifier.citedreference | Kim SYH, Wilson RM, Kim HM, et al. Comparison of enrollees and decliners of Parkinson disease sham surgery trials. Mov Disord 2012; 27: 506 – 511. | en_US |
dc.identifier.citedreference | Katsnelson A. Experimental therapies for Parkinson's disease: why fake it? Nature 2011; 476: 142 – 144. | en_US |
dc.identifier.citedreference | Alterman RL, Tagliati M, Olanow CW. Open‐label surgical trials for Parkinson disease: time for reconsideration. Ann Neurol 2011; 70: 5 – 8. | en_US |
dc.identifier.citedreference | Kim SYH, Frank S, Holloway R, Zimmerman C, Wilson R, Kieburtz K. Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers. Arch Neurol 2005; 62: 1357 – 1360. | en_US |
dc.identifier.citedreference | Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2‐neurturin for Parkinson's disease: a double‐blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1164 – 1172. | en_US |
dc.identifier.citedreference | LeWitt PA, Rezai AR, Leehey MA, et al. AAV2‐GAD gene therapy for advanced Parkinson's disease: a double‐blind, sham‐surgery controlled, randomised trial. Lancet Neurol 2011; 10: 309 – 319. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.